[Results] 46 weeks, 21kg, and orforglipron was the hard part
Six-word version is the title — 46 weeks, 21kg, and orforglipron was the hard part — and the rest is context.
The numbers the title promised, since a headline without them is worthless: 46 weeks and 21kg. Everything below is context for those.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
no food and water restrictions is the practical difference people care about
daily dosing, not weekly, so the exposure profile is different
identity testing on a small molecule is a different analytical problem
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.